<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011465</url>
  </required_header>
  <id_info>
    <org_study_id>1R21AG030632-01A2</org_study_id>
    <nct_id>NCT01011465</nct_id>
  </id_info>
  <brief_title>The Biology of Resilience</brief_title>
  <official_title>The Biology of Resilience: Oxytocin, Social Relationships and Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positive social relationships have consistently been associated with better health, although
      the neurobiological underpinnings of these observed effects remain largely unknown. The
      overall goal of the proposed work is to explore novel biological pathways that may explain
      how social relationships influence health. Recent theorizing suggests that the oxytocin
      system may underlie some of the observed beneficial effects. Four hypotheses will be
      examined:

        1. Oxytocin ameliorates the deleterious neuroendocrine, cardiovascular, and subjective
           effects of stress.

        2. Oxytocin and social support have similar and additive stress-buffering effects.

        3. Effects of oxytocin are evident among younger and older adults.

        4. Effects of oxytocin are stronger in women vs men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positive social relationships have consistently been associated with better health, although
      the neurobiological underpinnings of these observed effects are not well understood. Valuable
      insight may be gained by a life course perspective as it is becoming increasingly apparent
      that early life social experiences are crucially related to later life functioning and
      well-being. The overall goal of the proposed work is to explore novel biological pathways
      that help to explain how social relationships influence health. Recent theorizing on the
      biology relating positive social and emotional factors to health and patterns of resilience
      suggest that the oxytocin system may underlie some of the observed beneficial effects.
      Historically, most work on the oxytocin system in humans has been tied to reproductive
      outcomes (e.g., lactation), with more limited work on children and young adults. A growing
      body of experimental research with animals suggests that early in life, oxytocin not only
      creates powerful social bonds between a mother and child but may also stimulate growth and
      restorative processes as well as buffer deleterious stress-related neuroendocrine activation
      throughout the life course. Moreover, the animal literature has suggested that oxytocin is
      more potent in the presence of higher estrogen levels, leading investigators to hypothesize
      that effects of oxytocin are stronger in women than men, but few studies have tested this
      hypothesis in humans. A better understanding of the inter-relationships between oxytocin,
      social relationships, stress, and health will be gained by examining these factors in a
      controlled laboratory setting. The immediate goal of this research is to determine whether
      oxytocin plays a critical role in determining neuroendocrine, cardiovascular, and subjective
      responses to stress across age and gender, and to examine the effects of oxytocin in relation
      to those of social support. To achieve these goals, experimental research is proposed to
      examine the effects of exogenously administered (intranasal) oxytocin on psychological and
      physiological outcomes, under conditions of stress. The specific aims of this exploratory
      project are to test the following hypotheses:

        1. Oxytocin ameliorates the deleterious neuroendocrine, cardiovascular, and subjective
           effects of stress.

        2. Oxytocin and social support have similar and additive stress-buffering effects.

        3. Effects of oxytocin are stronger in women versus men.

        4. Effects of oxytocin are similar across a range of younger and older adult ages.

      Hypotheses will be tested via a placebo-controlled double blind study using a sample of
      healthy men and women recruited from the community (overall n = 320). The proposed
      experimental study will consider oxytocin effects on a range of outcomes. These include
      autonomic reactivity as measured by blood pressure responses and high frequency heart rate
      variability (measure of vagal tone). Stress-related cardiovascular phenotypes as
      characterized by the patterning of ventricle contractility, vascular resistance, and cardiac
      output will also be assessed. Other outcomes include measures of neuroendocrine effects as
      measured by levels of cortisol and dehydroepiandrosterone (DHEA) hormone, subjective distress
      and positive affect. Participants will be randomly assigned to receive either exogenous
      oxytocin or placebo. They will undergo a social stress manipulation with or without social
      support (randomly assigned), and outcome measures will be obtained at multiple times during
      the experimental procedure. The experiment will test whether effects of oxytocin and social
      support are similar and additive, and will also compare effects of oxytocin and social
      support across men and women of varying ages. This multidisciplinary study uses a
      biobehavioral framework to examine interactions between psychological, social, and biological
      levels of functioning, and is informed by theories of how key early life exposures may impact
      health over the life course. The provision of an R21 award for this work will facilitate
      novel research that could have a major impact on our understanding of whether and how
      oxytocin influences responses to stress in humans. The proposed exploratory research will lay
      the groundwork for the submission of an R01 grant proposal that will have greater resources
      for addressing both the questions that cannot be addressed with this more limited mechanism
      as well as new questions that will undoubtedly arise. Ultimately we expect this project will
      provide a solid platform from which to launch a larger program of research aimed at
      identifying how positive social and emotional experiences influence adult health and
      longevity. A neurobiological understanding of resilience can inform efforts for both
      prevention and intervention of diseases or problems common in later life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure</measure>
    <time_frame>within 2 hours of treatment</time_frame>
    <description>Systolic blood pressure (SBP)is connected with reaction to exposure to stress. Systolic blood pressure is collected at baseline and after nasal spray administration/directly before stress tasks; it represents anticipatory stress reaction. This measure represents the difference between baseline and pre-task systolic blood pressure values. A greater difference score represents an increase from baseline in systolic blood pressure during the pre-task, and so a larger difference score represents higher reactivity. A lower difference score, or negative difference score, indicates a lower increase, or even decrease, from baseline in systolic blood pressure during the pre-task and reflects less reactivity. Reactivity is associated with increased risk of developing hypertension. Range of baseline/pre-count differences in SBP: -11 to 37.7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference of Pre-count and Baseline Self-reported Negative Affect (Using Negative Sub-scale of Positive and Negative Affect Schedule (PANAS) Measure).</measure>
    <time_frame>2 hours</time_frame>
    <description>Based on 20-item Positive and Negative Affect Schedule (PANAS) which comprises two mood scales, positive affect and negative affect. Each item is rated on a 5-point scale ranging from (1 = very slightly or not at all) to (5 = extremely) to indicate how the respondent felt at the moment the question was asked. Here, we've used the negative affect sub-scale which consists of the sum of the 10 negative affect items, with a possible range of 10 (least negative affect) to 50 (most negative affect). This score was measured at baseline (study range: 10 to 29) and directly before stress exposure (study range: 10 to 37), and the reported value is the difference between these two scores (range of differences: -13 to 26). It estimates negative affect due to anticipatory stress. The value is the difference between the pre-stress measure and baseline measure, therefore a larger number for the difference means a bigger increase in negative affect due to anticipatory stress, and is a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speech Threat and Challenge</measure>
    <time_frame>2 hours</time_frame>
    <description>Measure of threat and challenge calculated from observation of non-verbal behavioral cues during stress exposure. Threat (negative reaction) results when an individual does not feel that he or she has sufficient resources to complete a task or manage a difficult situation. Its reverse, challenge (positive reaction), occurs when an individual perceives that he or she has sufficient resources. Independent observers used videotapes of behavior during the stress tasks and rated participants on 7 point scales for 11 challenge-related behaviors (comfortable, confident, enthusiastic, clear, alert, high level of eye contact, etc), and for 8 threat-related behaviors (agitation, rigid posture, speech disfluency, etc). Challenge scores were averaged, and threat scores averaged then reverse-scored. The mean of challenge and reversed threat scores comprise the score used here. Range: 1.1 to 6.1, with higher scores representing more challenge orientation and reflecting a better outcome.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Oxytocin</condition>
  <condition>Placebo</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Social Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Social Support</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female Gender</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Effects of oxytocin and social support are examined among women versus men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male Gender</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Consider effects of oxytocin and social support in men versus women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal oxytocin</intervention_name>
    <description>The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Social Support</arm_group_label>
    <arm_group_label>No Social Support</arm_group_label>
    <arm_group_label>Female Gender</arm_group_label>
    <arm_group_label>Male Gender</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Social Support</arm_group_label>
    <arm_group_label>No Social Support</arm_group_label>
    <arm_group_label>Female Gender</arm_group_label>
    <arm_group_label>Male Gender</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Social support</intervention_name>
    <description>Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Social Support</arm_group_label>
    <arm_group_label>Female Gender</arm_group_label>
    <arm_group_label>Male Gender</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No Social Support</intervention_name>
    <description>Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>No Social Support</arm_group_label>
    <arm_group_label>Female Gender</arm_group_label>
    <arm_group_label>Male Gender</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 22-65, BMI &lt; 30, healthy, English-speaking, 9th grade reading level.

        Exclusion Criteria:

          -  any known medical condition (including mental disorders) or on any type of medication

          -  high levels of social anxiety

          -  smokers

          -  high rates of alcohol or drug use

          -  pregnant or suspected pregnant

          -  breastfeeding

          -  blood pressures &gt; 140/90 mm Hg

          -  subject does not have a close friend available to participate in the study with
             him/her
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura D Kubzansky, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harvard School of Public Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kubzansky LD, Mendes WB, Appleton A, Block J, Adler GK. Protocol for an experimental investigation of the roles of oxytocin and social support in neuroendocrine, cardiovascular, and subjective responses to stress across age and gender. BMC Public Health. 2009 Dec 21;9:481. doi: 10.1186/1471-2458-9-481.</citation>
    <PMID>20025778</PMID>
  </reference>
  <results_reference>
    <citation>Kubzansky LD, Mendes WB, Appleton AA, Block J, Adler GK. A heartfelt response: Oxytocin effects on response to social stress in men and women. Biol Psychol. 2012 Apr;90(1):1-9. doi: 10.1016/j.biopsycho.2012.02.010. Epub 2012 Feb 23. Erratum in: Biol Psychol. 2013 Feb;92(2):97.</citation>
    <PMID>22387929</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>September 13, 2012</results_first_submitted>
  <results_first_submitted_qc>October 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2012</results_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard School of Public Health</investigator_affiliation>
    <investigator_full_name>Laura Kubzansky</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Stress</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Social Support</keyword>
  <keyword>Resilience</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in this study from 6/2008 to 4/2012. Initial screening was done by phone and email. Medical screening took place at a hospital clinic and the rest of the study took place at the Harvard School of Public Health.</recruitment_details>
      <pre_assignment_details>After initial screening , participants were asked to sign consent form and screened in a medical clinic prior to group assignment. Participants were excluded for violating study criteria, including having BMI&gt;30, high blood pressure, acute illness, smoking or drug use and chronic medical conditions. Refusal to sign consent also led to exclusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Female, OT, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="P2">
          <title>Female, OT, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="P3">
          <title>Female, Placebo, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="P4">
          <title>Female, Placebo, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="P5">
          <title>Male, OT, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="P6">
          <title>Male, OT, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="P7">
          <title>Male, Placebo, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="P8">
          <title>Male, Placebo, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="29"/>
                <participants group_id="P7" count="52"/>
                <participants group_id="P8" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="29"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Female, OT, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="B2">
          <title>Female, OT, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="B3">
          <title>Female, Placebo, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="B4">
          <title>Female, Placebo, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="B5">
          <title>Male, OT, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="B6">
          <title>Male, OT, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="B7">
          <title>Male, Placebo, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="B8">
          <title>Male, Placebo, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="29"/>
            <count group_id="B7" value="52"/>
            <count group_id="B8" value="32"/>
            <count group_id="B9" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="11.2"/>
                    <measurement group_id="B2" value="28.7" spread="6.2"/>
                    <measurement group_id="B3" value="34.3" spread="10.7"/>
                    <measurement group_id="B4" value="33.7" spread="13.2"/>
                    <measurement group_id="B5" value="34.8" spread="11.8"/>
                    <measurement group_id="B6" value="28.4" spread="9.0"/>
                    <measurement group_id="B7" value="36.0" spread="12.1"/>
                    <measurement group_id="B8" value="32.4" spread="9.7"/>
                    <measurement group_id="B9" value="33.2" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure</title>
        <description>Systolic blood pressure (SBP)is connected with reaction to exposure to stress. Systolic blood pressure is collected at baseline and after nasal spray administration/directly before stress tasks; it represents anticipatory stress reaction. This measure represents the difference between baseline and pre-task systolic blood pressure values. A greater difference score represents an increase from baseline in systolic blood pressure during the pre-task, and so a larger difference score represents higher reactivity. A lower difference score, or negative difference score, indicates a lower increase, or even decrease, from baseline in systolic blood pressure during the pre-task and reflects less reactivity. Reactivity is associated with increased risk of developing hypertension. Range of baseline/pre-count differences in SBP: -11 to 37.7</description>
        <time_frame>within 2 hours of treatment</time_frame>
        <population>All participants who received oxytocin or placebo, who completed the study, had relevant covariate data, and for whom systolic blood pressure was collected, were included</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Group</title>
            <description>Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.</description>
          </group>
          <group group_id="O3">
            <title>Female</title>
            <description>Effects of stress exposure examined among women versus men</description>
          </group>
          <group group_id="O4">
            <title>Male</title>
            <description>Effects of stress exposure examined among men versus women</description>
          </group>
          <group group_id="O5">
            <title>Social Support - Alone</title>
            <description>Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
          </group>
          <group group_id="O6">
            <title>Social Support - Friend</title>
            <description>Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure</title>
          <description>Systolic blood pressure (SBP)is connected with reaction to exposure to stress. Systolic blood pressure is collected at baseline and after nasal spray administration/directly before stress tasks; it represents anticipatory stress reaction. This measure represents the difference between baseline and pre-task systolic blood pressure values. A greater difference score represents an increase from baseline in systolic blood pressure during the pre-task, and so a larger difference score represents higher reactivity. A lower difference score, or negative difference score, indicates a lower increase, or even decrease, from baseline in systolic blood pressure during the pre-task and reflects less reactivity. Reactivity is associated with increased risk of developing hypertension. Range of baseline/pre-count differences in SBP: -11 to 37.7</description>
          <population>All participants who received oxytocin or placebo, who completed the study, had relevant covariate data, and for whom systolic blood pressure was collected, were included</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="8.2"/>
                    <measurement group_id="O2" value="12.9" spread="7.9"/>
                    <measurement group_id="O3" value="11.3" spread="9.3"/>
                    <measurement group_id="O4" value="11.1" spread="7.5"/>
                    <measurement group_id="O5" value="10.7" spread="7.4"/>
                    <measurement group_id="O6" value="11.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that both groups will have similar rise in SBP in response to stress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that both groups will have similar rise in SBP in response to stress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that both groups will have similar rise in SBP in response to stress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.01</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Difference of Pre-count and Baseline Self-reported Negative Affect (Using Negative Sub-scale of Positive and Negative Affect Schedule (PANAS) Measure).</title>
        <description>Based on 20-item Positive and Negative Affect Schedule (PANAS) which comprises two mood scales, positive affect and negative affect. Each item is rated on a 5-point scale ranging from (1 = very slightly or not at all) to (5 = extremely) to indicate how the respondent felt at the moment the question was asked. Here, weve used the negative affect sub-scale which consists of the sum of the 10 negative affect items, with a possible range of 10 (least negative affect) to 50 (most negative affect). This score was measured at baseline (study range: 10 to 29) and directly before stress exposure (study range: 10 to 37), and the reported value is the difference between these two scores (range of differences: -13 to 26). It estimates negative affect due to anticipatory stress. The value is the difference between the pre-stress measure and baseline measure, therefore a larger number for the difference means a bigger increase in negative affect due to anticipatory stress, and is a worse outcome.</description>
        <time_frame>2 hours</time_frame>
        <population>All participants who received oxytocin or placebo, who completed the study, had relevant covariate data, and for whom negative affect score was calculated, were included</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Group</title>
            <description>Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.</description>
          </group>
          <group group_id="O3">
            <title>Female</title>
            <description>Effects of stress exposure examined among women versus men</description>
          </group>
          <group group_id="O4">
            <title>Male</title>
            <description>Effects of stress exposure examined among men versus women</description>
          </group>
          <group group_id="O5">
            <title>Social Support - Alone</title>
            <description>Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
          </group>
          <group group_id="O6">
            <title>Social Support - Friend</title>
            <description>Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Pre-count and Baseline Self-reported Negative Affect (Using Negative Sub-scale of Positive and Negative Affect Schedule (PANAS) Measure).</title>
          <description>Based on 20-item Positive and Negative Affect Schedule (PANAS) which comprises two mood scales, positive affect and negative affect. Each item is rated on a 5-point scale ranging from (1 = very slightly or not at all) to (5 = extremely) to indicate how the respondent felt at the moment the question was asked. Here, weve used the negative affect sub-scale which consists of the sum of the 10 negative affect items, with a possible range of 10 (least negative affect) to 50 (most negative affect). This score was measured at baseline (study range: 10 to 29) and directly before stress exposure (study range: 10 to 37), and the reported value is the difference between these two scores (range of differences: -13 to 26). It estimates negative affect due to anticipatory stress. The value is the difference between the pre-stress measure and baseline measure, therefore a larger number for the difference means a bigger increase in negative affect due to anticipatory stress, and is a worse outcome.</description>
          <population>All participants who received oxytocin or placebo, who completed the study, had relevant covariate data, and for whom negative affect score was calculated, were included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="152"/>
                <count group_id="O5" value="158"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="4.5"/>
                    <measurement group_id="O2" value="1.8" spread="4.1"/>
                    <measurement group_id="O3" value="2.1" spread="4.7"/>
                    <measurement group_id="O4" value="1.2" spread="3.9"/>
                    <measurement group_id="O5" value="1.8" spread="4.9"/>
                    <measurement group_id="O6" value="1.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states that both groups will have similar PANAS negative affect score change in response to stress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states that both groups will have similar PANAS negative affect score change in response to stress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states that both groups will have similar PANAS negative affect score change in response to stress.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Speech Threat and Challenge</title>
        <description>Measure of threat and challenge calculated from observation of non-verbal behavioral cues during stress exposure. Threat (negative reaction) results when an individual does not feel that he or she has sufficient resources to complete a task or manage a difficult situation. Its reverse, challenge (positive reaction), occurs when an individual perceives that he or she has sufficient resources. Independent observers used videotapes of behavior during the stress tasks and rated participants on 7 point scales for 11 challenge-related behaviors (comfortable, confident, enthusiastic, clear, alert, high level of eye contact, etc), and for 8 threat-related behaviors (agitation, rigid posture, speech disfluency, etc). Challenge scores were averaged, and threat scores averaged then reverse-scored. The mean of challenge and reversed threat scores comprise the score used here. Range: 1.1 to 6.1, with higher scores representing more challenge orientation and reflecting a better outcome.</description>
        <time_frame>2 hours</time_frame>
        <population>All participants who received oxytocin or placebo, who completed the study, had relevant covariate data, and for whom speech threat score was calculated, were included</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin Group</title>
            <description>Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.</description>
          </group>
          <group group_id="O3">
            <title>Female</title>
            <description>Effects of stress exposure examined among women versus men</description>
          </group>
          <group group_id="O4">
            <title>Male</title>
            <description>Effects of stress exposure examined among men versus women</description>
          </group>
          <group group_id="O5">
            <title>Social Support - Alone</title>
            <description>Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
          </group>
          <group group_id="O6">
            <title>Social Support - Friend</title>
            <description>Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
          </group>
        </group_list>
        <measure>
          <title>Speech Threat and Challenge</title>
          <description>Measure of threat and challenge calculated from observation of non-verbal behavioral cues during stress exposure. Threat (negative reaction) results when an individual does not feel that he or she has sufficient resources to complete a task or manage a difficult situation. Its reverse, challenge (positive reaction), occurs when an individual perceives that he or she has sufficient resources. Independent observers used videotapes of behavior during the stress tasks and rated participants on 7 point scales for 11 challenge-related behaviors (comfortable, confident, enthusiastic, clear, alert, high level of eye contact, etc), and for 8 threat-related behaviors (agitation, rigid posture, speech disfluency, etc). Challenge scores were averaged, and threat scores averaged then reverse-scored. The mean of challenge and reversed threat scores comprise the score used here. Range: 1.1 to 6.1, with higher scores representing more challenge orientation and reflecting a better outcome.</description>
          <population>All participants who received oxytocin or placebo, who completed the study, had relevant covariate data, and for whom speech threat score was calculated, were included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="140"/>
                <count group_id="O6" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.0"/>
                    <measurement group_id="O2" value="4.6" spread="1.0"/>
                    <measurement group_id="O3" value="4.5" spread="1.0"/>
                    <measurement group_id="O4" value="4.6" spread="1.0"/>
                    <measurement group_id="O5" value="4.6" spread="0.9"/>
                    <measurement group_id="O6" value="4.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states that both groups had similar threat/challenge scores during the speech task.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states that both groups had similar threat/challenge scores during the speech task.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states that both groups had similar threat/challenge scores during the speech task.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the course of the study, ~ 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Female, OT, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="E2">
          <title>Female, OT, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="E3">
          <title>Female, Placebo, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="E4">
          <title>Female, Placebo, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among women versus men.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="E5">
          <title>Male, OT, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="E6">
          <title>Male, OT, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Intranasal oxytocin : The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin is administered.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
        <group group_id="E7">
          <title>Male, Placebo, Alone</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Alone : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. Participant assigned to alone is unaccompanied during tasks.</description>
        </group>
        <group group_id="E8">
          <title>Male, Placebo, Friend</title>
          <description>Effects of intranasal oxytocin and social support examined among men versus women.
Placebo : Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo is administered at one time only during the procedure. Approximately half the dose is sprayed into each nostril. Administration stops after the full amount in the spray bottle has been used.
Social support - Friend : Prior to lab visit, participant is randomly assigned to one of two conditions, requiring them to appear alone or accompanied by partner. If instructed to bring a same-sex close friend (excluding spouses), participants are joined by their support partners at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data collected earlier in the study is missing blood pressure data due to technical problems.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Laura Kubzansky</name_or_title>
      <organization>Harvard School of Public Health</organization>
      <phone>617-432-3589</phone>
      <email>lkubzans@hsph.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

